HighGravityDataExact Sciences — Nov 3, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001124140-25-000090
Showing in the filing
Precision Oncology Y/Y growth rate
“9%”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 10
Revenue midpoint increase for FY2025
“$78 million”
Adjusted EBITDA midpoint increase for FY2025
“$10 million”
Screening Y/Y growth rate for FY2025
“20%”
Total revenue for FY2025
“$3.220 - $3.235 billion”
Total revenue Y/Y growth rate for FY2025
“17%”
Screening for FY2025
“$2.510 - $2.520 billion”
Precision Oncology for FY2025
“$710 - $715 million”
Adjusted EBITDA for FY2025
“$470 - $480 million”
Adjusted EBITDA Y/Y growth rate for FY2025
“47%”
Precision Oncology Y/Y growth rate for FY2025
“9%”
Exhibit 99.1 · the passage around this item
… earlier in the release
GAAP to Non-GAAP Reconciliation Core Revenue (Unaudited) (Amounts in thousands) GAAP Three Months Ended September 30, 2025 2024 % Change Screening $ 666,240 $ 544,901 22 % Precision Oncology 184,499 163,754 13 % Total $ 850,739 $ 708,655 20 % Non-GAAP Three Months Ended September 30, 2025 2024 (1) % Change Foreign Currency Impact (2) Core Revenue (3) % Change (3) Screening $ 666,240 $ 544,901 22 % $ — $ 666,240 22 % Precision Oncology 184,499 163,193 13 % (1,334) 183,165 12 % Total $ 850,739 $ 708,094 20 % $ (1,334) $ 849,405 20 % GAAP Nine Months Ended September 30, 2025 2024 % Change Screening $ 1,834,728 $ 1,551,305 18 % Precision Oncology 533,881 494,138 8 % Total $ 2,368,609 $ 2,045,443 16 % Non-GAAP Nine Months Ended September 30, 2025 2024 (1) % Change Foreign Currency Impact (2) Core Revenue (3) % Change (3) Screening $ 1,834,728 $ 1,551,305 18 % $ — $ 1,834,728 18 % Precision Oncology (4) 533,881 488,963 9 % (4,072) 529,809 8 % Total $ 2,368,609 $ 2,040,268 16 % $ (4,072) $ 2,364,537 16 % (1) Excludes revenue from the divested Oncotype DX Genomic Prostate Score test, which ceased generating revenue at the completion of a transition period in the third quarter of 2024. (2) Foreign currency impact is calculating the change in current period non-U.S. dollar denominated revenue using the prior year comparative period exchange rates. (3) Excludes revenue from the divested Oncotype DX Genomic Prostate Score test for the three and nine months ended September 30, 2024 and the impact of foreign currency exchange rate fluctuations. (4) Includes sublicense revenue of $7.5 million for the nine months ended September 30, 2025 that was recognized under a sublicense agreement executed in the second quarter of 2025 related to technology licensed from TwinStrand Biosciences, Inc. in the third quarter of 2024. EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Adjusted EBITDA (Unaudited) (Amounts in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net loss $ (19,594) $ (38,236) $ (121,994) $ (164,272) Interest expense 9,789 9,607 29,6
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.